High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility.
Three newborn infants who developed hyperbilirubinemia due to blood group incompatibility were treated with high-dose gammaglobulin. Hyperbilirubinemia was caused by Rhesus (Rh) incompatibility (anti-E + anti-c) in Infant 1 and ABO incompatibility (anti-B) in Infants 2 and 3. Hyperbilirubinemia was refractory to conventional phototherapy but responded well to intravenous gammaglobulin (IVGG) at a dose of 1 g/kg in all infants. No adverse effects were observed. These findings suggest that high-dose IVGG may be useful in the treatment of hyperbilirubinemia due to isoimmune haemolytic disease resistant to phototherapy.
Sato
K
K
Department of Neonatology, Medical Center for Sick Children and Infectious Disease, Fukuoka, Japan.
Hara
T
T
Kondo
T
T
Iwao
H
H
Honda
S
S
Ueda
K
K
D004338:Drug Combinations; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous; D007231:Infant, Newborn; D008297:Male; D005719:gamma-Globulins / Q000008:administration & dosage*
D004338:Drug Combinations; D016756:Immunoglobulins, Intravenous; D005719:gamma-Globulins; D005341:Fibrinolysin